Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)
暂无分享,去创建一个
M. Genovese | P. Emery | G. Silverman | Li Xie | P. Berclaz | W. Komocsar | M. Veenhuizen | Chin H Lee | Ramesh C. Gupta | A. Gill | L. Xie